Prospective studies with larger sample sizes are needed to evaluate the correlation between PD-L1 expression, clinical response, and survival, and to establish the predictive value of PD-L1 expression, CD8+ TILs, and BRAFV600E mutation in thyroid cancer. This evidence concerns the gene CD8A and thyroid cancer.